AMD Phenotype and Genotype Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01778491
Recruitment Status : Completed
First Posted : January 29, 2013
Last Update Posted : April 5, 2018
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Eye Institute (NEI) )

Brief Summary:


- Age-related macular degeneration (AMD) is a disease that blurs the sharp vision needed for activities such as reading, sewing, and driving. It affects the macula, the center of the retina at the back of the eye, which allows a person to see fine detail. Researchers want to collect medical histories, eye exam data, and genetic information that may be associated with AMD. They want to compare this information with information collected from people without AMD.


- To collect medical information and gene samples for researchers studying AMD.


  • Individuals between and 60 and 90 years of age who have AMD in at least one eye.
  • Individuals between and 60 and 90 years of age who have no AMD in either eye.


  • This study will involve one study visit. This study visit will last 6 to 8 hours.
  • Participants will have the following tests and exams as part of their study visit:
  • Full physical exam and medical history
  • Full eye examination
  • Laser scan of the eye
  • Retina function test
  • Vision sensitivity test
  • Optional blood sample (for genetic study)
  • No treatment will be provided as part of this study.

Condition or disease
Age-Related Macular Degeneration AMD

Detailed Description:

Objective: Late age-related macular degeneration (AMD) is the leading cause of blindness among elderly in the United States. At present the current classification systems do not take into consideration advances in imaging technology and genotyping and phenotyping.

Clinical centers in the US and around the world will conduct a pilot cohort study that will bring together resources and commitment to test the feasibility of developing a new classification scheme for AMD using imaging and visual function biomarkers, with the potential of correlating genetic information obtained in the future. These data could eventually help develop an understanding of the mechanisms involved in the development and progression of AMD. A database of men and women with and without AMD will be established and maintained. The project will recruit participants who have various stages of AMD and controls. The pilot study will identify the feasibility of obtaining imaging and visual function data and help identify which of these modalities should be included in a full scale longitudinal study, as well as how frequently and at which sites they should be obtained. All data, images and any potential biospecimens from the full scale longitudinal study will be available to researchers worldwide to help in the development of biomarker identification and classification development. The initiative should provide an unparalleled state-of-the-art standardized phenotype/genotype including AMD status with information on imaging, visual function, and biospecimen biomarkers. This study is the first phase of this initiative to test the feasibility and logistics of defining a standard database including enhanced phenotype and genotype data.

Study Population: This cohort study will recruit a minimum of 200 total participants with various stages of AMD, including controls and obtain the appropriate images and measures of visual function needed for the investigation and validation of an AMD phenotype.

Design: This cohort study is a multi-national, multi-center, observational study focused on AMD. The study is a pilot to test the ability to create an archive of data, biological samples (collected at other study sites), measures of visual function and ophthalmic images collected over time from a very well clinically characterized population of participants with a diagnosis of AMD. The database will also include a control group consisting of participants without a diagnosis of AMD.

Outcome Measures: The design of this cohort study and the data being collected will allow users to assess phenotypes of AMD, develop and evaluate potential markers and risk factors, develop and evaluate an AMD classification scheme(s), and assess the progression of the disease and investigate factors that shape it. It is not practical to anticipate all of the potential uses of the data, or all the types of analyses that will be performed to address user-defined questions.

Study Type : Observational
Actual Enrollment : 344 participants
Time Perspective: Prospective
Official Title: AMD Phenotype and Genotype Study (APGS)
Study Start Date : November 5, 2012
Actual Primary Completion Date : September 29, 2015
Actual Study Completion Date : September 29, 2015

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Primary Outcome Measures :
  1. Allow users to assess phenotypes of AMD [ Time Frame: 5 years ]
  2. Develop and evaluate potential markers and risk [ Time Frame: 5 years ]
  3. Develop and evaluate an AMD classification scheme(s) [ Time Frame: 5 years ]
  4. Assess the progression of the disease and investigate that shape it. [ Time Frame: 5 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   60 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

To be eligible, the following inclusion criteria must be met, where applicable.

-Male or female participants must fall into any of the following categories:

  • No drusen or any AMD-associated pigment abnormalities (no apparent aging changes)
  • Small drusen (less than or equal to 63 micro millimeters in diameter) and the absence of AMD-associated pigment abnormalities in either eye (normal aging changes)
  • Medium (>63 (Micro)m and less than or equal to 125 micro millimeters in diameter) drusen in either eye (Early AMD)
  • Large (>125 (Micro)m in diameter) drusen with or without pigmentary abnormalities in either eye (Intermediate AMD)
  • Neovascular AMD in only one eye or the presence of geographic atrophy in either eye but with vision >20/60 in the better-seeing eye (Late AMD)
  • Presence of reticular Drusen in either eye

AMD classification will be based on clinical evaluation.

  • 60 years of age or older
  • Ability to provide written informed consent and comply with study assessments for the full duration of the study
  • Retinal photographs of sufficient quality to allow assessment of the macular area for AMD lesions including drusen


A participant is not eligible if any of the following exclusion criteria are present:

  • Presence of lens or vitreous opacity in eye(s) with AMD to preclude adequate ophthalmic imaging
  • Presence of ocular conditions that may now or in the future complicate the evaluation of AMD [e.g., vascular occlusion, diabetic retinopathy (>4 microaneurysms), etc.] in the eye(s) with AMD
  • High myopia -6 Diopters or more severe
  • Diagnosis of nystagmus
  • Glaucoma with definite visual field defects. Participants with a history of the diagnosis of glaucoma, past or present use of medications to control intraocular pressure, or disc/nerve fiber layer defects suggestive of glaucoma can be eligible for the study if they have a documented normal Goldmann, Humphrey, or Octopus perimetry test within 6 months prior to qualification.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01778491

United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892
University of Bonn
Bonn, Germany
Sponsors and Collaborators
National Eye Institute (NEI)
Principal Investigator: Emily Y Chew, M.D. National Eye Institute (NEI)

Responsible Party: National Eye Institute (NEI) Identifier: NCT01778491     History of Changes
Other Study ID Numbers: 130027
First Posted: January 29, 2013    Key Record Dates
Last Update Posted: April 5, 2018
Last Verified: September 29, 2015

Keywords provided by National Institutes of Health Clinical Center (CC) ( National Eye Institute (NEI) ):
Phenotype-Genotype correlation
Age Related Macular Degeneration

Additional relevant MeSH terms:
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases